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delivery increased FPA levels (12.5 +=3.5 vs. 2.8 & 0.8 rig/ml, p = 0.019)
compared with patients without events. Patients with events had significantly
increased FPA levels prior to (18.9 + 4.1 vs. 6.1 + 1.1 n~ml, p = 0.001) and
after PTCA (11.8+3.8 vs. 5.1 + 1.9 rig/ml, p =0.03). SUrnrnary:PTCA in the
setting of increased FPA levels was associated with an increased event rate
at 8 month follow-up. Intramural delivery of urokinase increased the clinical
event rate over a 8 month follow-up. The results support the hypothesis
that increased thrombin activity and/or thrombin formation plays a role in
restenosis.
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El8021 CPKRiseAfterSaphenousVeinGraftIntervention:AngiogrsphicPredictorssndClinicalOutcomes
S.R. Bailey, D. Snead, R.S. Kiesz, M. Savage, D.L. Fischman, J. Douglas,
C. Pepine, J. Werner, R. Rake, S. Goldberg. The University of TexasHealth
SCMIC.S Cefrter@San AntoniO,San Antonio, Texas,USA
Saphenous vein graft interventions (SVGI) are associated with a significant
risk of distal embolization and CPK elevation. CPK elevations in native
vesaels are associated with increased clinical events after interventions. We
report the substudy analyaia from the Saphenous Vein De novo (SAVED)trial
evaluating CPK elevations in the 223 lesions from 220 patients randomized
to balloon angioplasty (6A) or Palmaz Schatz (PS) stent.
We evaluated the correlates of CPK elevation stratified as <2x, 2 – 5x
and >5x normal. No difference in CPK rise was noted between PS or BA
groups. CPK rise correlated with larger vessel size (3.16+ 0.55 mm vs 3.91
+ 0.72 mm) P <0.001, and lesions longer than 15 mm (P c 0.01) but not
angiographic thrombus or graft age. Balloon to artery ratios were smaller
and maximal inflation pressures lowerin patients with CPK elevation. CPK
elevation predicted longer hospital stays (5.1 +5.4 days vs 12.2 +8.2 days,
p < 0.01) and an increased riakof death (1/177< 2x, 1/17 >2 <5x, 2/6 >5x,
P < 0.001). We conclude that 1) CPK elevation during SVGI occurred more
frequently in larger vessels and longer lesions consistent with greater plaque
burden. 2) CPK elevation =- 5 x normal was associated with more frequent
early Ml and death. 3) CPK elevation was not relatedto high pressure inflation
over sized balloons or grafl age.
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El8022 ContemporaryPercutaneousTreatmentofUnprotectedLeftMeinCoronaryStenoses- An
Updatefromthe ULTIMARegistry
S,G. Ellis, H. Tamai, M. Nobuyoshi, A. Colomtm, D.R. Holmes, K. Kosuga,
C.L. Grines for the ULTIMA Regist~. Cleveland C/inic Foundation,
Cleveland, OH, USA
Recent single site experience with debulking and stenting of unprotected left
main stenoses (ULMS) has led to a re-evaluation of the role of percutaneous
treatment (perc m) in theee patients (pts). To amalgamate experience with
perc rx of ULMS, we formed a Registry 3/96 and have reported preliminary
results (n = 38). The purpose of this report is to update our experience (n =
100), focusing on pt subgroups,
Subgroup In-hospitalDesth 6 Month(%) Restenosis Death cOmD
(%) (%) (%)
3fableangina(n=46) &5 29.7 19.6 19.6
Unetableanghra[n =41) 14.6 48.1 39.0 48.7
CABGcandidate*(n= 66) 4.6 28.6 16,9 19.0
RsfueedforCABG*(n= 21) 23.8 85.7 65.0 70.0
Stent*(n=42) 0,0 33.3 t9,0 32.6
DCA*(n= 24) 6,3 21.7 12,5 12.5
Othsrtraatment*(n= 21) 28.8 70.0 47,6 47.9
*excludes pta withacute Ml, Comp=cardiac death, Ml, or CABG
These preliminary data suggest: 1) when perc m of ULMS is necessary,
stent or DCAia preferred; 2) although stent/DCAforstable angina and CABG
candidate gives fair results, except for a 3-5% incidence of sudden death
within 6 mea, resulte with other groups appear unfavorable: 3) Perc rx of
ULMS with present technoiogyshould be performed cautiously,perhaps with
angiogrephic follow-up at 2-3 mos to identify pts with early (and petiaps
life-threatening) restenosie.
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ChronicCoronaryArteryOcclusion:Reductionof
Restenosis-andReocclusion-RatesbvStent
Treatment
D.G. Mathey, A. Seidensticker, T. Rau, K.-P. Kunze, J. Schofer. Cerrferfor
Cardiology Hamburg-Othmarschen, Germany
Recanalization of chronic coronary artery occlusions by balloon angioplasty
is associated with a non-occlueive restenosis rate of about 30% and a
raocclusion rate of about 20%. It was the “objective of this study to eesese
restenosis- and reocclusion-rates after stent placement and to determine
factors predicting restenosie and reocclusion.
In 143 patients chronic coronary occlusions were recanalized and sub-
sequently treated by stenting. Stentimplantation was performed with high-
-pressure dilatation (14-18 atm) using mainly Palmaz-Schatz and AVE-
Microstents. Medical treatment was with ASA (100 mg/d) in combination with
ticlopidine for 4-12 weeks. Control angiography was performed in 120/143
patients 10 to 40 weeks (mean 19 weeks) after successful recenalization.
Repeat angiography revealed no restenosis in 67 vessels (72Yo).Restenosis
?50?4was found in 34 vessels (26%) including reocclusion in 7 vessels (6%).
Vessels with restenosis had a significantly smaller minimal Iuminal diameter
(MLD) after stent-implantation as compared to vessels without reatenosia (p
= 0.03); vessels which were reoccluded at follow-up had a smaller MLD anda
smaller reference diameter as compared to vessels without reocclusion (p <
0.03). Symptoms of the patients were markedly improved. At follow-up nearly
60% of patients were asymptomatic whereas prior to intervention more than
70% of patients were in CCS-Class 2 or higher.
Conclusions: 1.Stent treatment of chronic coronary artery occlusion
cleartyreducesthe restenosisand reocclusion rate. 2. Symptoms are markedly
reduced or abolished in most of the patients. 3. MLD after the procedure and
the diameter of the reference segment were significant predictors of resteno-
siehocclusion after stent treatment for chronic occlusion.
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1802-41stentin~insma,,vesse,s:ARe*va,uationusing~he
GRIIIntracoronaryStentine MulticenterRegistry
Study
L.S. Dean, J.P. Zidar, W.D. Voorhees, DR. Holmes, Jr.,
C.D. O’Shaughnessy, P.B. Moore, E.W. Rogers, R.R. Heuser, G.S. Roubin,
M.B. Leon for the Cook GRII investigator. University Of A/abaf7r8 at
Birmingham, Birmingham, AL, USA
Previous experiences using corona~ stents in small vessels have produced
mixed results. To determine the safety and efficacy of the newly designed
GRII atent in small (<3.0 mm) vessels, a multicenter registry waeformed and
thusfar, 21 centers have enrolled 128 patients. C/inica/demographics: 62.5%
males, mean age 62.4 + 11.6 years, 32.6% prior Ml, 80% de novo lesions,
84.8% multivessel disease, and.mean ejection fraction 58.2+ 11.3%. Lesion
characteristics: mean vessel diameter 2.8 + 0.4 mm, lesion length 12.5 +
6.2 mm, B2 and C leaions 63.6%, diffuse diaease 35.29’o,and moderate
or severe proximal tortuosity 327.. Procedural details: stent sizes were 2.5
mm in 36.1% and 3.0 mm in 55.4%. Post-stent high pressure (=-14 atm)
adjunct PTCA was routinely applied without frequent ultrasound guidance
and the routine anticoagulation regimen was aspirin plus ticlopidine. Resu/fs:
Angiographic success was achieved in 99.2% of patients. 30-day clinical
outcomes include death in 0.6%, CABG in 0.8Y0,no Q-wave Ml’s, subacute
stent thrombosis in 3.1%, and repeat PTCA in 2.3%. In conclusion:The new
GRII stent (1) can be used to treat complex lesions in tortuous small veesels
with vety high success rates and (2) major adverse events (death, Ml, CABG,
or repeat PTCA) are infrequent in the firat thirty days. Thus, if late follow-
up results are similarly favorable, future clinical trials would be indicated to
assesethe relative value of the GRII stent compared with conventional PTCA
in small vessels.
